Fig. 5: SBI-0646535, but not OLZ, was equally effective in mitigating MK-801-induced functional changes in Ovx rats.

All data shown are group means ± SEM. The percent change from baseline in 10-min bins across the 7-h recording period was evaluated in O-I (A, E), Ovx (B, F), and Ovx+E rats (C, G). OLZ and SBI-0646535 were administered at time point 0 followed by vehicle or MK-801 30 min later (denoted by arrows). On the x-axis, −2 corresponds to ZT 0 and 5 corresponds to ZT 7. Then, direct group comparisons were evaluated as the average % change within the high gamma power band in the 60–180 min post-dosing period (D, main effect of dose: F_{2.723, 57.19} = 44.29, p < 0.0001; H, main effect of dose: F_{1.753, 35.94} = 32.96; p < 0.0001). p < 0.05; in timecourse graphs (A–C and E–G), horizontal colored lines matching the respective dose color represent the 10 min bins at which OLZ- or SBI-0646535-treated groups were significantly different from groups treated with vehicle + 0.1 mg/kg MK-801. In D, H, a, compared to the group’s respective vehicle + 0.1 mg/kg MK-801 condition. n = 8 O-I, 7–8 Ovx, and 8 Ovx+E rats.